Carol Green, Senior Director, Preclinical Development | SRI International

Toggle Menu

Carol Green

Senior Director, Preclinical Development

Carol Green, Ph.D., DABT, is an accomplished scientist with expertise in toxicology, absorption, distribution, metabolism, and excretion studies. In her current role, she is the principal investigator for four National Institutes of Health contracts and one research grant.

Her research includes developing new in vitro human tissue models to predict toxicity of pharmaceuticals and environmental chemicals, and advancing the preclinical development of promising pharmaceutical candidates against chemical threat agents. She also provides preclinical pharmacology and toxicology data on anti-infective agents, cancer chemopreventive and therapeutic agents, and other pharmaceuticals. Green oversees the development of data included in Investigational New Drug applications and has served on project teams for more than 10 drugs that have moved into Phase I trials.

Green has authored or co-authored 57 published papers and 98 abstracts. She is a diplomate for the American Board of Toxicology, and past president of the Genetic and Environmental Toxicology Association of Northern California. She received a Ph.D. in pharmacology and toxicology from the University of California, Davis, and conducted postdoctoral work in biochemical toxicology at SRI.

Carol Green